Putting a Spotlight on Systemic Mastocytosis A Multidisciplinary Look at Early Diagnosis and Management

Mariana C. Castells, MD; Tracy I. George, MD; Matthew J. Hamilton MD; Karin Hartmann, MD

This activity is jointly provided by Global Education Group and Integritas Communications. This activity is endorsed by The Mast Cell Disease Society, Inc.


This educational activity is supported by an educational grant from Blueprint Medicines Corporation.


Mariana C. Castells, MD, PhD
Professor of Medicine
Harvard Medical School
Director, Drug Hypersensitivity and Desensitization Center
Director, Mastocytosis Center
Associate Physician, Brigham and Women’s Hospital
Boston, Massachusetts

Tracy I. George, MD
Professor of Pathology
University of Utah School of Medicine
President and Chief Medical Officer
ARUP Laboratories
Salt Lake City, Utah

Matthew J. Hamilton MD
Assistant Professor of Medicine
Harvard Medical School
Lead Gastroenterologist
Brigham and Women’s Hospital Mastocytosis Center
Boston, Massachusetts

Karin Hartmann, MD
Chair, Division of Allergy
Deputy Chair, Department of Dermatology
Professor of Medicine
University Hospital Basel and University of Basel
Basel, ‎Switzerland

Program Description

Systemic mastocytosis (SM) is a group of rare disorders characterized by accumulation of mast cells in internal tissues and organs, such as the liver, spleen, bone marrow, and small intestines. Patients with SM experience symptoms that include anaphylaxis, flushing, gastrointestinal issues, fatigue, and skin lesions; the lack of specific symptoms often makes diagnosis challenging, and clinicians should be aware of the array of symptoms and signs that indicate SM. More than 90% of patients with SM have a KIT D816V mutation, which, along with serum tryptase and bone marrow biopsy, is key to diagnosing SM. Management strategies for nonadvanced SM are largely symptomatic treatment, though there are targeted therapies in clinical trials. During this Clinical Research Updates™ webcast, a multidisciplinary expert panel will review the evidence and best-practice recommendations for the early diagnosis and treatment of SM, including keys to differential diagnosis, recommendations for management, and results and progress from new clinical trials. Included within this educational activity is an “Ask the Experts” chat box feature, allowing learners to submit questions that will be answered by program faculty.

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, dermatologists, gastroenterologists, and other specialist clinicians positioned to identify patients with SM.

Learning Objectives

After completing this activity, participants will be better prepared to:

  1. Describe current World Health Organization diagnostic criteria for systemic mastocytosis (SM) and disease subtyping
  2. Differentially diagnose SM, including nonadvanced cases, based on symptomology, disease subtypes, and appropriate ancillary testing
  3. Discuss clinical profiles and trial evidence for current and emerging treatment options in nonadvanced SM, including pharmacodynamics data 
  4. Explain how to facilitate the management of patients with nonadvanced SM via early diagnosis, evidence-based treatment, appropriate referrals, and access to ongoing clinical trials

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Disclosure of Conflicts of Interest

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global Education Group are required to disclose all financial relationships with any ineligible company within the past 24 months to Global Education Group. All financial relationships reported are identified as relevant and mitigated by Global Education Group in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global Education Group to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mariana C. Castells, MD, PhD - nothing to disclose

Tracy I. George, MDConsulting fee: Blueprint Medicines Corporation, Incyte Corporation, Celgene Corporation, BluPrint Oncology Concepts, UBC (United BioSource LLC), Allakos Inc.; Contracted Research: Blueprint Medicines Corporation, Incyte Corporation, Celgene Corporation, Deciphera Pharmaceuticals, LLC, Cogent Biosciences, Inc.; all received by ARUP Laboratories

Matthew J. Hamilton MD - Consulting Fee: Allakos Inc., GlaxoSmithKline

Karin Hartmann, MD - Consulting Fee: Novartis Pharma AG, Takeda Pharma AG, Thermo Fisher Scientific Inc., LEO Pharmaceutical Products Sarath Ltd., Rallybio, Sanofi-Aventis (Suisse) SA, Pfizer AG; Contracted Research: Blueprint Medicines Corporation

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Kim Rodriguez: Nothing to disclose
Gena Dolson, MS: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to received credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation.

Term of Offering

This activity was released on December 22, 2021, and is valid for one year. Requests for credit must be made no later than December 22, 2022. 

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Education Group Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 1.00

credit type CME/AANP

release 12/22/2021

expiration 12/22/2022

type Webcast